Tobira Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss CENTAUR Phase 2b Trial Results

SOUTH SAN FRANCISCO, Calif.--()--Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Monday, July 25 to discuss Phase 2b results for cenicriviroc in patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.

Teleconference/Webcast Details

Listen via Internet: http://ir.tobiratx.com/

Toll-free: 1 (855) 638-8858

International: +1 (707) 294-1299

Access code: 55407004

A webcast replay will be available on the Tobira website for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 55407004.

About Tobira Therapeutics

Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to serious liver damage. Tobira’s pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at www.tobiratx.com.

Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.

©2016 Tobira Therapeutics, Inc. All Rights Reserved.

Contacts

Tobira Investor & Media Contact:
Ian Clements, Ph.D., +1 650-351-5013
ir@tobiratx.com
or
BrewLife Media Contact:
Kelly Boothe, Ph.D., +1 415-946-1076
kboothe@brewlife.com

Tobira Therapeutics, Inc.